相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
Akito Hata et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2022)
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
Akito Hata et al.
ONCOLOGY AND THERAPY (2022)
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study
Peipei Ye et al.
ANNALS OF HEMATOLOGY (2022)
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
Toshinobu Hayashi et al.
BMC CANCER (2021)
5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer
Toshinobu Hayashi et al.
CANCER SCIENCE (2021)
Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database
Yuji Kunitomi et al.
SUPPORTIVE CARE IN CANCER (2021)
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2021)
Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China
Yu Sun et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis
Toshinobu Hayashi et al.
SUPPORTIVE CARE IN CANCER (2021)
Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
Yoshitaka Saito et al.
SCIENTIFIC REPORTS (2021)
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Laurent Zelek et al.
ONCOLOGIST (2021)
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Yoichi Naito et al.
BREAST CANCER (2020)
Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
Karin Melanie Cabanillas Stanchi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2020)
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo et al.
BONE MARROW TRANSPLANTATION (2020)
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial
Ramavath D. Naik et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy
Mototsugu Shimokawa et al.
ANTICANCER RESEARCH (2019)
Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy
L. Lee Dupuis et al.
PEDIATRIC BLOOD & CANCER (2019)
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2018)
Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial
L. Lee Dupuis et al.
CANCER (2018)
Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan
Yasushi Tsuji et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)
Shunsuke Ohnishi et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial
Wolfgang Marx et al.
NUTRIENTS (2017)
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin
P. Bossi et al.
ANNALS OF ONCOLOGY (2017)
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
Steven Trifilio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
Hirotoshi Iihara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
Yosuke Ando et al.
SUPPORTIVE CARE IN CANCER (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen
Yoshiharu Miyata et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
Hirotoshi Iihara et al.
JOURNAL OF CANCER (2016)
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan
Kazuo Tamura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
Satoe Fujiwara et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance)
Debra L. Barton et al.
CANCER (2014)
The Effectiveness of Acupressure for the Control and Management of Chemotherapy-Related Acute and Delayed Nausea: A Randomized Controlled Trial
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy
Yosuke Ikari et al.
SUPPORTIVE CARE IN CANCER (2014)
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
I. N. Olver et al.
SUPPORTIVE CARE IN CANCER (2013)
Nausea and Vomiting Perspectives Among Children Receiving Moderate to Highly Emetogenic Chemotherapy Treatment
Cheryl Rodgers et al.
CANCER NURSING (2012)
Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis
Chiao-En Wu et al.
SUPPORTIVE CARE IN CANCER (2012)
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients
Xiaorong Dong et al.
MEDICAL ONCOLOGY (2011)
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen et al.
SUPPORTIVE CARE IN CANCER (2007)
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
J Vardy et al.
BRITISH JOURNAL OF CANCER (2006)
Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11
M Ikeda et al.
EUROPEAN JOURNAL OF CANCER CARE (2005)
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study
P Eisenberg et al.
ANNALS OF ONCOLOGY (2004)
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
MS Aapro et al.
ANNALS OF ONCOLOGY (2003)
Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer
S Sagae et al.
ONCOLOGY (2003)
Treatment of nausea and emesis during cancer chemotherapy:: Discrepancies between antiemetic effect and well-being
S Börjeson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869 - A randomized controlled trial
S Van Belle et al.
CANCER (2002)
An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy
A Molassiotis et al.
EUROPEAN JOURNAL OF CANCER CARE (2002)
Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients
A Molassiotis et al.
SUPPORTIVE CARE IN CANCER (2002)
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer
M Fujii et al.
SUPPORTIVE CARE IN CANCER (2001)
Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration
R Maisano et al.
SUPPORTIVE CARE IN CANCER (2001)
A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting
A Molassiotis
EUROPEAN JOURNAL OF CANCER CARE (2000)
Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone - A crossover study of triple 8-mg dose of ondansetron
CC Liaw et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
分享论文
